Boehringer Ingelheim announces new milestones for the novel oral anticoagulant Pradaxa® (dabigatran etexilate) with over two million patient-years of experience in all licensed indications globally.
via Education - Latest News http://www.prlog.org/12209565-pradaxa-drives-boehringer-ingelheims-innovation-promise-in-cardiovascular-diseases-napsr-announces.html
via Education - Latest News http://www.prlog.org/12209565-pradaxa-drives-boehringer-ingelheims-innovation-promise-in-cardiovascular-diseases-napsr-announces.html
No comments:
Post a Comment